Tesamorelin
Tesamorelin — approved daily schedule
Also called Egrifta, TH9507, tesamorelin protocol
2 mg daily, from an approved label, with a 52-week pooled analysis behind it.
Combination evidence: Strong
Where every number on this page comes from
Each quantity carries one of these five labels. They are not interchangeable, and the difference between the first and the last is the difference between a regulated finding and a rumour with a number attached.
- FDA labelling
- This figure appears in FDA-approved product labelling for an approved indication. It is the strongest warrant on this site.
- Published study arm
- This figure is the quantity administered in a named arm of the linked study. It describes what was studied, not what is advised.
- Clinical guideline
- This figure appears in published clinical or professional guidance.
- Manufacturer protocol
- This figure comes from a manufacturer or investigator document rather than from peer-reviewed literature.
- Community practice — no trial
- No clinical trial has tested this figure. It reflects what is commonly reported in practice and carries no evidentiary weight. It is shown because it is what circulates, and because showing it with this label is more useful than pretending it does not exist.
The figure most often reported for each compound. Where a compound has no separately sourced figure at this level, its most commonly reported figure is used instead, and the citation beneath it says so.
Duration
52 weeks
1 phase
Administrations
364
about 7/week at peak
Vials required
364
1 compound
Cost at this plan
$3,780.00
Peptira, list price
Phase by phase
Weeks 1–52 · 52 weeks
Daily administration
One subcutaneous injection daily into the abdomen.
Tesamorelin
Once daily · Subcutaneous
Most commonly reported, per dose
2 mgPublished study arm
2 mg daily · Pooled phase 3 analysis, PMID 20554713 · in the study register
Prepared at 2 mg in 2 mL
Every quantity above is one administration. At once daily, that is 14.00 mg per week.
| Concentration | 1.00 mg/mL | Draw volume | 2.000 mL |
| Pull to (U-100) | 200.0 units | Doses per vial | 1 |
| This phase | 364 administrations | Vials, this phase | 364 |
Why it is here
Daily administration; the effect on visceral fat reversed on discontinuation in the published follow-up.
What is not known
Studied in adults with HIV-associated lipodystrophy. Effect size and safety in an otherwise healthy population are not established.
What you would need to buy
Vial counts are computed by simulating consumption, not by dividing total milligrams. Those two disagree whenever a vial cannot be finished, which is most of the time, and dividing under-buys.
| Compound | Vial | Administrations | Total material | Vials |
|---|---|---|---|---|
| TesamorelinDaily administration | 2 mg | 364 | 728.00 mg | 364 |
| Total | 364 | 364 | ||
What it would cost
List prices from each vendor’s own product pages, with the date each figure was read. Quantity tiers are applied where a vendor publishes them.
Loti Labs
Prices as of 2026-08-24
$6,005.47
$16.50/day · $502.22/month
| TesamorelinTesamorelin 10mg · 10 mg$8.00/mg listed · $8.02/mg after what expires unusedPriced at the 10 mg size rather than the 2 mg this plan assumes, because across the sizes this vendor stocks it works out cheapest for the whole course. Vial count re-simulated at that strength. | 73 × $79.99 | $5,839.27 |
| Bacteriostatic water30ML Reconstitution Solution · 30 mLThis plan uses 146.0 mL across every reconstitution. 4.0 mL is left over, because bottles do not divide.Sold as a reconstitution solution rather than under the name bacteriostatic water. The page describes 0.9% benzyl alcohol as the preservative. | 5 × $33.24 | $166.20 |
| Syringes364 administrations, so 364 syringes. None of the vendors priced on this site sells syringes, alcohol pads or a sharps container. They are ordinary pharmacy items in most places and restricted in some. The count below is what the plan requires; where to obtain them is outside what this site can tell you. | 364 × — | Not sold here |
| Total, compounds and water | $6,005.47 | |
Above this vendor's published $99 free-shipping threshold.
We earn nothing from this link. Loti Labs has no affiliate programme.
Pure Health Peptides
Prices as of 2026-08-24
$17,910.27
$49.20/day · $1,497.77/month
| TesamorelinTesamorelinThis listing is sold in several vial sizes and the figure shown is the cheapest one, so the real price is higher. The listing does not publish a vial size, so the vial count is the plan's own and may not match what ships. | 364 × $47.00 | $17,108.00 |
| Bacteriostatic waterBacteriostatic Water · 10 mLThis plan uses 728.0 mL across every reconstitution. 2.0 mL is left over, because bottles do not divide.The only size this vendor sells. Stock was reported as one unit remaining when read. | 73 × $10.99 | $802.27 |
| Syringes364 administrations, so 364 syringes. None of the vendors priced on this site sells syringes, alcohol pads or a sharps container. They are ordinary pharmacy items in most places and restricted in some. The count below is what the plan requires; where to obtain them is outside what this site can tell you. | 364 × — | Not sold here |
| Total, compounds and water | $17,910.27 | |
Above this vendor's published $175 free-shipping threshold.
We earn nothing from this link. No affiliate programme was found for this vendor.
Peptira
Prices as of 2026-08-25
$3,843.75
$10.56/day · $321.44/month
| TesamorelinTesamorelin | 30MG · 30 mg$5.04/mg listed · $5.19/mg after what expires unusedPriced at the 30 mg size rather than the 2 mg this plan assumes, because across the sizes this vendor stocks it works out cheapest for the whole course. Vial count re-simulated at that strength. | 25 × $151.20 | $3,780.00 |
| Bacteriostatic waterBAC Water 10ML · 10 mLThis plan uses 50.0 mL across every reconstitution. | 5 × $12.75 | $63.75 |
| Syringes364 administrations, so 364 syringes. None of the vendors priced on this site sells syringes, alcohol pads or a sharps container. They are ordinary pharmacy items in most places and restricted in some. The count below is what the plan requires; where to obtain them is outside what this site can tell you. | 364 × — | Not sold here |
| Total, compounds and water | $3,843.75 | |
Above this vendor's published $250 free-shipping threshold.
Peptira runs an affiliate programme. This site has not applied to it, so no commission is earned on this link today.
List price is not the price anyone pays
What usually goes wrong
Ranked by how often it happens rather than by how serious it sounds.
Expecting the effect to persist after stopping
Visceral fat returned toward baseline after discontinuation in the published follow-up. This is a maintained-effect compound.
Confusing the two approved presentations
Egrifta and Egrifta SV have different labelled quantities. Check which product the figure came from before doing any arithmetic.
What is worth measuring
Markers that would actually tell you something, and what each one tells you. Nothing here is a requirement, and none of it substitutes for a clinician who knows your history.
| Marker | When | What it tells you |
|---|---|---|
| IGF-1 | Baseline and periodically | This is a GHRH analogue; IGF-1 is the downstream marker. |
| Fasting glucose and HbA1c | Baseline and periodically | Glucose intolerance was reported in the trials. |
Populations this was not studied in
An absence of evidence in a group is not evidence of safety in that group. These are listed because the gap itself is the finding.
- Active malignancy — labelled contraindication
- Pregnancy
- Populations without HIV-associated lipodystrophy
Related protocols
Semaglutide
The 16-week step-up written into the approved label, with the arithmetic done for each step.
Tirzepatide
Labelled 2.5 mg steps to a 5, 10, or 15 mg maintenance, with 176-week follow-up behind it.
Retatrutide
What the published phase 2 arms actually administered. Not approved, and not a label.
Protocol last reviewed 2026-08-24. Every quantity on this page carries its own source. If you find one that does not, that is a bug and the build should have caught it.